Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This study will evaluate two groups of patients who have melanoma that has spread from the
eye to the liver: one group (50%) will get high-dose chemotherapy delivered specifically to
the liver, while the other group (50%) will get one of 4 standard best alternative care
treatments. Patients in each group will get repeating cycles of treatment until the cancer
in the liver advances and will be followed until death. This study will evaluate the effect
of the treatments on how long patients live and how long it takes for the cancer to advance
or respond to the treatment.